Drug testing devices firm Lifeloc's Q3 revenue rises

Lifeloc Technologies

12/11/2025 21:47

Overview

Lifeloc Q3 2025 revenue increased 8% year-over-year to $2.257 mln

Company reported a net loss of $263,000 for Q3 2025

Gross margin decreased to 40.2% in Q3 due to cost inflation and tariffs

Outlook

Lifeloc expects to launch SpinDetect™ in 2026

Company sees rapid oral-fluid drug testing as key growth opportunity

Lifeloc's acquisition of ELST aims to strengthen market reach

Result Drivers

R&D COSTS - High research and development expenses for SpinDetect™ drug analyzer commercialization contributed to net loss

COST INFLATION AND TARIFFS - Gross margin decline attributed to general cost inflation and tariffs, company plans pricing adjustments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$2.26 mln
Q3 EPS
-$0.10
Q3 Net Income
-$263,000
Q3 Gross Margin
40.20%


Press Release: ID:nACSQTphMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)